DLT may not be best metric for trials of non-cytotoxic agents

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1316, 2010-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Design of Phase II Cancer Trials for Evaluation of Cytostatic/Cytotoxic Agents

By Kocherginsky Masha Cohen Ezra Karrison Theodore

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 524-529

Taylor & Francis Ltd

Access to resources Recommend Favorite

Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects

By Martin Lainie Schilder Russell J.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 9, 2006-10 ,pp. : 955-966

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Non-Cytotoxic Radiosensitizers in Brain Radiotherapy: Journey Till the First Decade of this Millennium

Current Cancer Drug Targets, Vol. 12, Iss. 3, 2012-03 ,pp. : 260-278

Bentham Science Publishers

Access to resources Recommend Favorite

Cationic Lipid-Coated Gold Nanoparticles as Efficient and Non-Cytotoxic Intracellular siRNA Delivery Vehicles

By Kong Won Bae Ki Jo Sung Kim Jee Park Tae

Pharmaceutical Research, Vol. 29, Iss. 2, 2012-02 ,pp. : 362-374

Springer Publishing Company

Access to resources Recommend Favorite

Dinuclear Cyclam Complex as a Non-Cytotoxic, Anti-Hyperurecemic Lead: In vitro to In vivo Studies

Medicinal Chemistry, Vol. 13, Iss. 6, 2017-08 ,pp. : 585-591

Bentham Science Publishers

Access to resources Recommend Favorite